ARTICLE
27 January 2015

EPA To Propose Health Care Facility-Specific Regulations For The Management Of Hazardous Waste Pharmaceuticals Under RCRA

B
BakerHostetler

Contributor

BakerHostetler logo
Recognized as one of the top firms for client service, BakerHostetler is a leading national law firm that helps clients around the world address their most complex and critical business and regulatory issues. With five core national practice groups — Business, Labor and Employment, Intellectual Property, Litigation, and Tax — the firm has more than 970 lawyers located in 14 offices coast to coast. BakerHostetler is widely regarded as having one of the country’s top 10 tax practices, a nationally recognized litigation practice, an award-winning data privacy practice and an industry-leading business practice. The firm is also recognized internationally for its groundbreaking work recovering more than $13 billion in the Madoff Recovery Initiative, representing the SIPA Trustee for the liquidation of Bernard L. Madoff Investment Securities LLC. Visit bakerlaw.com
EPA plans to propose new regulations this year to address the management of hazardous waste pharmaceuticals under the Resource Conservation and Recovery Act.
United States Environment
To print this article, all you need is to be registered or login on Mondaq.com.

EPA plans to propose new regulations this year to address the management of hazardous waste pharmaceuticals under the Resource Conservation and Recovery Act (RCRA). The agency anticipates issuing a notice of proposed rulemaking on this issue in June 2015, according to its updated regulatory agenda, the availability of which was announced in the Federal Register on December 22, 2014 (79 Fed. Reg. 76,772).

EPA previously issued a notice of proposed rulemaking on this topic in December 2008 (73 Fed. Reg. 73,520). Its 2008 proposal would have added hazardous waste pharmaceuticals to the Universal Waste Rule, which modifies RCRA's hazardous waste regulations to streamline the management of certain hazardous wastes. EPA explained at the time that it hoped the approach would facilitate the implementation of pharmaceutical take-back programs. But after receiving adverse public comment on the proposal, EPA did not follow up with a final rule. In its online discussion "Management of Hazardous Waste Pharmaceuticals," EPA explains that "comment on the December 2008 proposal revealed numerous concerns over the lack of notification requirements for those facilities that generate, handle or transport 'universal waste' pharmaceuticals as well as for the lack of tracking requirements for the shipment of these wastes."

Now, six years later, EPA is gearing up for a second attempt to promulgate new regulations for hazardous waste pharmaceuticals. It appears that EPA will be taking a different approach than it did in 2008 when its proposal focused on adding pharmaceutical hazardous wastes to the Universal Waste Rule. According to its regulatory agenda, EPA is now considering "health care facility-specific regulations for the management of hazardous waste pharmaceuticals in order to provide a regulatory scheme that is adapted to the unique issues that hospitals, pharmacies and other health care-related facilities face." On its website, EPA states that its new proposal will also address "the concerns raised by the public comments regarding notification and tracking issues[.]"

As with the 2008 proposed rule, the publication of the new proposed rule later this year will likely garner extensive public comments. Unless and until new final regulations are promulgated, generators of hazardous waste pharmaceuticals will continue to be subject to the RCRA Subtitle C generator requirements.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More